Hereditary Cancer

Our suite of hereditary cancer tests uses next generation sequencing to detect clinically relevant gene variants for many cancer syndromes. Identification of these variants can help providers determine individual and familial cancer risk, develop additional screening and monitoring strategies, and develop treatment plans.

Chromosomal Abnormalities (Cytogenetics)

Cytogenetics testing aids in the diagnosis of heritable genetic abnormalities and the detection of acquired abnormalities relevant for the diagnosis, prognosis, therapy, and monitoring of many types of cancer.

Our comprehensive cytogenetics laboratory offers testing for both constitutional and oncology cases, including chromosome analysis, fluorescence in situ hybridization (FISH) analysis, and genomic microarray.

Pharmacogenomic Testing

Pharmacogenomic testing leverages genetic testing to predict a patient’s response to a drug and achieve therapeutic efficacy. We provide affordable, high-throughput testing based on genes with the highest levels of evidence to provide results that will effectively help clinicians manage their patients’ treatment plans.

Noninvasive Prenatal

Our noninvasive prenatal testing (NIPT) uses next generation, whole genome sequencing to assess the risk that a fetus will be born with chromosomal abnormalities. NIPT provides a cost-effective, sensitive, and specific screening option for trisomy 13, trisomy 18, and trisomy 21.

Pregnancy and Prenatal

Our pregnancy and prenatal tests can be used to determine the risk for heritable genetic disease, screen for and diagnose chromosomal abnormalities, and monitor the health of both fetus and mother throughout pregnancy. We also offer diagnostic testing for at-risk pregnancies through our cytogenetics and molecular genetics labs, as well as testing to determine the underlying cause of infertility or pregnancy loss.